Xbrane Biopharma AB

Aims to take protein production in E. coli to the next level. The company enables their customers to produce their proteins in a controllable system, with higher yields and better quality.

More than 60% of all pharmaceutical target proteins and the majority of all new pharmaceuticals and vaccines, are protein-based. In research and development, and production of these protein-based therapeutics, finding the optimal conditions for protein production is often a time-consuming and laborious process. Xbrane Biopharma has two tightly-controlled bacterial protein expression systems. They enable expression of host-toxic and challenging proteins, as well as high yields of soluble proteins.